Burrill & Co. swells its life sciences fund to $505M

Amidst a tepid venture capital environment in the world of biotechnology, one VC firm has restocked its war chest to the tune of $505 million. San Francisco's Burrill & Co. closed its latest fund and looks to invest in healthcare and life sciences firms, including makers of devices, diagnostics and therapeutics. Report

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.